These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 24911972)

  • 21. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
    Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
    J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
    Alves R; Queiroz AT; Pessoa MG; da Silva EF; Mazo DF; Carrilho FJ; Carvalho-Filho RJ; de Carvalho IM
    J Viral Hepat; 2013 Jun; 20(6):414-21. PubMed ID: 23647958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
    Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
    Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
    McPhee F; Hernandez D; Zhou N; Ueland J; Yu F; Vellucci V; Huang X; Wang X; Ishikawa H; Karino Y; Kumada H
    Antivir Ther; 2018; 23(1):53-66. PubMed ID: 28594332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.
    Uchida Y; Kouyama J; Naiki K; Sugawara K; Ando S; Nakao M; Motoya D; Inao M; Imai Y; Nakayama N; Mochida S
    J Gastroenterol; 2016 Mar; 51(3):260-70. PubMed ID: 26245700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
    Di Maio VC; Barbaliscia S; Teti E; Fiorentino G; Milana M; Paolucci S; Pollicino T; Morsica G; Starace M; Bruzzone B; Gennari W; Micheli V; Yu La Rosa K; Foroghi L; Calvaruso V; Lenci I; Polilli E; Babudieri S; Aghemo A; Raimondo G; Sarmati L; Coppola N; Pasquazzi C; Baldanti F; Parruti G; Perno CF; Angelico M; Craxì A; Andreoni M; Ceccherini-Silberstein F;
    Liver Int; 2021 Aug; 41(8):1802-1814. PubMed ID: 33497016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
    Kileng H; Kjellin M; Akaberi D; Bergfors A; Duberg AS; Wesslén L; Danielsson A; Gangsøy Kristiansen M; Gutteberg T; Goll R; Lannergård A; Lennerstrand J
    Scand J Gastroenterol; 2018; 53(10-11):1347-1353. PubMed ID: 30394152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment.
    Bagaglio S; Andolina A; Merli M; Uberti-Foppa C; Morsica G
    Viruses; 2016 Mar; 8(4):91. PubMed ID: 27023593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis.
    Santos APT; Silva VCM; Mendes-Corrêa MC; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; Castro VFD; Pinho JRR; Moreira RC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e61. PubMed ID: 36197422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.
    Grandal M; Pernas B; Tabernilla A; Mariño A; Álvarez H; Valcarce N; Mena A; Castro-Iglesias A; Pérez AB; Delgado M; Poveda E
    J Med Virol; 2018 Jun; 90(6):1094-1098. PubMed ID: 29427437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.
    Vidal LL; Soares MA; Santos AF
    J Viral Hepat; 2016 Nov; 23(11):840-849. PubMed ID: 26775769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and persistence of DAA resistance associated mutations in patients failing HCV treatment.
    Paolucci S; Fiorina L; Mariani B; Landini V; Gulminetti R; Novati S; Maserati R; Barbarini G; Bruno R; Baldanti F
    J Clin Virol; 2015 Nov; 72():114-8. PubMed ID: 26489401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
    Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
    J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
    Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
    Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
    Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus.
    Peres-da-Silva A; de Almeida AJ; Lampe E
    J Antimicrob Chemother; 2015 Mar; 70(3):726-30. PubMed ID: 25414201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.
    Bartels DJ; Sullivan JC; Zhang EZ; Tigges AM; Dorrian JL; De Meyer S; Takemoto D; Dondero E; Kwong AD; Picchio G; Kieffer TL
    J Virol; 2013 Feb; 87(3):1544-53. PubMed ID: 23152524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.